Anbio Biotechnology filed a Form F-1 registration statement for an initial public offering on 2024-12-31. It has amended it 3 times. It filed its final prospectus on 2025-02-19. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our Class A Ordinary Shares have been approved for listing on Nasdaq Global Market under the symbol “NNNN”.From the 424B4 filed 2025-02-19
Shares offered
We are offering 1,600,000 Class A ordinary shares, par value US$0.0001 per share (the “Class A Ordinary Shares”), of Anbio Biotechnology (“Anbio”, the “Company”, “we”, “our”, “us”), a Cayman Islands exempted company.From the 424B4 filed 2025-02-19
Use of proceeds
We intend to use the net proceeds of this offering primarily for expansion of sales and distribution network in the strategically selected markets, research and development, and working capital and general corporate matters.From the 424B4 filed 2025-02-19
Revenue
For the six months ended June 30, 2024 and 2023, we generated revenue of $5.85 million and $3.06 million, respectively, of which 44% and 99% were from respiratory diseases and COVID -19 related products.From the F-1/A filed 2025-01-10
Net loss or income
We generated a net income of $2,253,709 for the year ended December 31, 2023, as compared to $10,011,177 for the year ended December 31, 2022, a decrease of $7,757,468 or approximately 77.5%, predominately due to reasons as discussed above.From the F-1/A filed 2025-01-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-12-31 | Registration statement filed (foreign issuer) | F-1 |
| 2025-01-10 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-01-24 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-02-10 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-02-19 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Anbio Biotechnology. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.